Private Trust Company’s Pacira BioSciences PCRX Stock Holding History

Private Trust Company’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-91	Closed	-$2.6K	–	2343
2024 Q2	$2.6K	Hold	91	–	–	﹤0.01%	2112
2024 Q1	$2.66K	Hold	91	–	–	﹤0.01%	2071
2023 Q4	$3.07K	Buy	91 +30	+49%	+$878	﹤0.01%	2053
2023 Q3	$1.87K	Hold	61	–	–	﹤0.01%	2132
2023 Q2	$2.44K	Sell	61 -8	-12%	-$331	﹤0.01%	2073
2023 Q1	$2.82K	Hold	69	–	–	﹤0.01%	2013
2022 Q4	$3K	Hold	69	–	–	﹤0.01%	1947
2022 Q3	$4K	Hold	69	–	–	﹤0.01%	1750
2022 Q2	$4K	Buy	+69	New	+$4.52K	﹤0.01%	1820
2014 Q4	–	Sell	-9	Closed	-$1K	–	926
2014 Q3	$1K	Buy	+9	New	+$876	﹤0.01%	1768

Other funds holding PCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

DPCM

Doma Perpetual Capital Management Miami, Florida $372M AUM 14.96% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Private Trust Company's PCRX Position: Q3 2024 in Review

Private Trust Company sold out of Pacira BioSciences (PCRX) in Q3 2024, closing a stake of 91 shares — an estimated $2.6K sold.

Private Trust Company first reported a position in PCRX in Q3 2014 and held it in 10 quarters. The position peaked at $4K in Q3 2022. 239 funds tracked by Wall St. Rank hold PCRX as of Q3 2024.

Private Trust Company reported no remaining Pacira BioSciences position as of Q3 2024 after selling out during the quarter.
Private Trust Company sold 91 Pacira BioSciences shares in Q3 2024, an estimated $2.6K.
Private Trust Company first reported a position in Pacira BioSciences in Q3 2014 and held it in 10 quarters.
Private Trust Company's Pacira BioSciences position peaked at $4K in Q3 2022.
239 funds tracked by Wall St. Rank held Pacira BioSciences as of Q3 2024.

Based on Private Trust Company's 13F filing for Q3 2024, filed 13 Nov 2024.